Abstract: An imaging structure identification system includes an optical imaging system configured to illuminate a liquid biopsy sample for a subject. The liquid biopsy sample has one or more biological structures that are labeled with one or more fluorophores associated with a fluorescence assay for a disease state allowing detection of emitted electromagnetic radiation from the liquid biopsy sample as image data. The system also includes a processing system configured to identifying the subject as being at reduced risk for having the disease state if the subject profile is similar to the first predetermined profile for subjects not being in the disease state. However, if the subject profile is not similar to the first predetermined profile for subjects not being in the disease state it is not determinative if the subject is in the disease state.

Abstract: A method for the longitudinal control of a vehicle according to a target trajectory specifying a series of target positions to be adopted by the vehicle over time. Based on an actual status of the vehicle, a control acceleration is determined for the purpose of trajectory control, by which the vehicle is to be accelerated according to specifications of the target trajectory. Based on an actual speed of the vehicle and a predefined maximum speed which should not be exceeded when travelling the target trajectory, a control acceleration for the purpose of speed control is determined, by which the vehicle is to be accelerated in order to travel at the maximum speed. Both control accelerations are supplied to an arbiter which determines a resulting control acceleration from same, wherein the vehicle is accelerated according to the resulting control acceleration. A device for the longitudinal control of the vehicle is provided.

Abstract: A method and device for longitudinal control of a vehicle as a function of a target trajectory, which specifies a series of target positions to be assumed by the vehicle over time. A controller actuating acceleration for trajectory control is determined based on an actual state of the vehicle. When the vehicle is following the target trajectory, a curvature of the target trajectory at a current position of the vehicle is determined from a local course of the target trajectory. Furthermore, when the vehicle is following the target trajectory, a longitudinal acceleration resulting from the target trajectory is determined as the current trajectory acceleration at the current position of the vehicle and the controller actuating acceleration is limited to a value that corresponds at most to a sum of the current trajectory acceleration and the acceleration offset. The vehicle is accelerated in accordance with the limited controller actuating acceleration.

Abstract: A system for identification of a biological structure present in a liquid biopsy sample is provided. The system identifies common biological structures and rare biological structures based on their fluorescence characteristics and morphology. The identified biological structures may be used in diagnosis and treatment of a human afflicted with a disease. Examples described in this disclosure also relate to methods and assays that may be used together with the systems of this disclosure for diagnosis and treatment of a human afflicted with a disease.

Abstract: The present invention provides methods for predicting response to a hormone-directed therapy or chemotherapy in a prostate cancer (PCa) patient comprising (a) performing a direct analysis comprising immunofluorescent staining and morphological characteristization of nucleated cells in a blood sample obtained from the patient to identify and enumerate circulating tumor cells (CTC); (b) individually characterizing genotypic, morphometric and protein expression parameters to generate a profile for each of the CTCs, and (c) predicting response to hormone-directed therapy in the prostate cancer PCa patient based on said profile. In some embodiments, the methods comprise repeating steps (a) through (c) at one or more timepoints after initial diagnosis of prostate cancer to sequentially monitor said genotypic, morphometric and protein expression parameters.

Abstract: The present invention provides methods for diagnosing lung cancer in a subject comprising (a) generating circulating tumor cell (CTC) data from a blood sample obtained from the subject based on a direct analysis comprising immunofluorescent staining and morphological characteristics of nucleated cells in the sample, wherein CTCs are identified in context of surrounding nucleated cells based on a combination of the immunofluorescent staining and morphological characteristics; (b) obtaining clinical data for the subject; (c) combining the CTC data with the clinical data to diagnose lung cancer in the subject.

Abstract: The invention provides seminal computational approaches utilizing data from non-rare cells to detect rare cells, such as circulating tumor cells (CTCs). The invention is applicable at two distinct stages of CTC detection; the first being to make decisions about data collection parameters and the second being to make decisions during data reduction and analysis. Additionally, the invention utilizes both one and multi-dimensional parameterized data in a decision making process.

Abstract: Methods, systems, and apparatus for a method that predicts an individual survival survival time of a patient. The method includes obtaining clinical data associated with health factors of the patient. The method includes obtaining liquid biopsy data associated with one or more attributes of diseased cells within the patient. The method includes predicting or determining a survival time of the patient using a deep learning model based on the clinical data and the liquid biopsy data. The method includes providing or outputting the survival time.

Abstract: The disclosure provides methods for detecting circular endothelial cells (CECs) in a non-enriched blood sample. The present disclosure is based, in part, on the unexpected discovery that CECs can be detected in non-enriched blood samples. The present disclosure is further based, in part, on the discovery that CECs can be detected in non-enriched blood samples by combining the detection of one or more immunofluorescent markers in the nucleated cells of a non-enriched blood sample with an assessment of the morphology of the nucleated cells. The present disclosure is further based, in part, on the discovery that CECs can be detected in non-enriched blood samples by comparing the immunofluorescent marker staining and morphological characteristics of CECs with the immunofluorescent marker staining and morphological characteristics of WBCs. The methods disclosed herein serve to classify human subject in myocardial infarction (MI) patients or healthy controls.

Abstract: This disclosure relates to a system for determining a quantitative health-related performance status of a patient. This disclosure further relates to a health assessment method for quantitative determination of health-related performance or quality of life of a patient. More specifically, this disclosure relates to systems and methods for determining whether a cancer patient will need unplanned medical care during cancer therapy. This system may comprise at least one sensor and at least one processor. The system may be configured to generate at least one output signal conveying physical activity information corresponding to physical activity of the patient, or spatial position information corresponding to at least one spatial position of an anatomical site of the patient while the patient performs a movement. The system may further be configured to determine a quantitative health-related performance score of the patient based on the physical activity parameter or the kinematic parameter.

Abstract: Human performance is a predictor of survival and response to chemotherapy in patients with cancer. It may be used to initiate new treatment, and monitor patients during ongoing treatment for early signs of deterioration when additional support can still be provided to restore performance and optimize treatment outcomes. This disclosure describes systems and methods for determining whether a cancer patient will need unplanned medical care during cancer therapy (e.g., necessitated by deterioration during cancer therapy). The systems and methods described herein are configured such that the determination is based on an acceleration of patient's center of mass during a prescribed movement, and/or metabolic equivalence determined based on the tracking of a patient's daily activities.

Abstract: The present invention provides methods for identifying circulating melanoma cells (CMCs) in a biological sample and methods for diagnosing metastatic melanoma in a subject. The methods disclosed can be used on non-enriched blood samples to identify CMC using detectable agents that are specific for a biomarker of CMCs and assessing the morphology of the cells having the detectable agents. The presence or absence of a detectable agent in combination with morphological characteristics of the cells can be used diagnose a subject with metastatic melanoma based on the number of CMCs is present in the sample.

Abstract: Methods are provided for detecting circulating tumor cells in a mammalian subject. Methods of diagnosing cancer in a mammalian subject are provided. The methods of detection or diagnosis indicate the presence of metastatic cancer or early stage cancer.

Abstract: The present invention provides methods for diagnosing lung cancer in a subject comprising (a) generating circulating tumor cell (CTC) data from a blood sample obtained from the subject based on a direct analysis comprising immunofluorescent staining and morphological characteristics of nucleated cells in the sample, wherein CTCs are identified in context of surrounding nucleated cells based on a combination of the immunofluorescent staining and morphological characteristics; (b) obtaining clinical data for the subject; (c) combining the CTC data with the clinical data to diagnose lung cancer in the subject.

Abstract: The present invention provides methods for predicting response to a hormone-directed therapy or chemotherapy in a prostate cancer (PCa) patient comprising (a) performing a direct analysis comprising immunofluorescent staining and morphological characteristization of nucleated cells in a blood sample obtained from the patient to identify and enumerate circulating tumor cells (CTC); (b) individually characterizing genotypic, morphometric and protein expression parameters to generate a profile for each of the CTCs, and (c) predicting response to hormone-directed therapy in the prostate cancer PCa patient based on said profile. In some embodiments, the methods comprise repeating steps (a) through (c) at one or more timepoints after initial diagnosis of prostate cancer to sequentially monitor said genotypic, morphometric and protein expression parameters.

Abstract: A device includes an antenna array with at least four antennas, wherein each antenna has its own feeder line terminal, wherein the feeder line terminals of antennas arranged directly adjacent to one another are geometrically offset from one another by 90° in each case. The device further includes a control device configured to feed the individual antennas via their respective feeder line terminals such that the antenna array exhibits different radiation patterns at different points in time. A first radiation pattern shows a polarized field distribution. According to the invention, a second radiation pattern exhibits an unpolarized field distribution.

Abstract: Methods, systems, and apparatus for a method that predicts an individual survival survival time of a patient. The method includes obtaining clinical data associated with health factors of the patient. The method includes obtaining liquid biopsy data associated with one or more attributes of diseased cells within the patient. The method includes predicting or determining a survival time of the patient using a deep learning model based on the clinical data and the liquid biopsy data. The method includes providing or outputting the survival time.

Abstract: A transceiver for distance measurements between the transceiver and an apparatus is provided. The transceiver has a transmitter configured to emit a first signal portion to be emitted at a first center frequency and a second signal portion to be emitted at a second center frequency so that the first signal portion to be emitted is radiated back from the apparatus to the transceiver as a first reflected signal portion and so that the second signal portion to be emitted is radiated back from the apparatus to the transceiver as a second reflected signal portion. In addition, the transceiver has a receiver configured to receive the first reflected signal portion radiated back from the apparatus to the transceiver and the second reflected signal portion radiated back from the apparatus to the transceiver. Furthermore, the transceiver has a measuring module configured to determine a distance between the transceiver and the apparatus.

Abstract: The invention provides seminal computational approaches utilizing data from non-rare cells to detect rare cells, such as circulating tumor cells (CTCs). The invention is applicable at two distinct stages of CTC detection; the first being to make decisions about data collection parameters and the second being to make decisions during data reduction and analysis. Additionally, the invention utilizes both one and multi-dimensional parameterized data in a decision making process.